2Steven W.Johnson,James P.et al.Cisplatin and Its Analogues[M].Cancer:Principles and Practice of Oncology,6th Edition.Lippincott Williams ＆ Wilkins,USA,2001:380-382.
3McHugh PJ,Spanswick VJ,Hartley JA.Repair of DNA interstrand crosslinks:molecular mechanisms and clinical relevance [J].Lancet Oncol,2001,2:483-490.
4Lehmann AR.Workshop on Eukaryotic DNA repair genes and gene products [J].Cancer Res,1995,55:968-970.
5Dabholkar M,Bostick Bruton F,Weber C,et al.ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients [J].J Natl Cancer Inst,1992,84(19):1512-1517.
6Metzger R,Leichman CG,Danenberg KD,et al.ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy[J].J Clin Oncol,1998,16(1):309-316.
7Monzo M,Rosell R,Taron M.Drug resistance in non small cell lung cancer [J].Lung Cancer,2001,34 Suppl 2:S91-94.
8Wood D,Klein E,Fair W,Chaganti R.Metallothionein gene expression in bladder cancer exposed to cisplatin [J].Mod Pathol,1993,6:33.
9Kotoh S,Naito S,Sakamoto N,et al.Metallothionein expression is correlated with cisplatin resistance in transitional cell carcinoma of the urinary tract [J].J Urol,1994,152(4):1267-1270.
10Siu L,Banerjee D,Khurana F,et al.The prognostic role of p53,metallothionein,P-glycoprotein,and MIB-1 in muscle-invasive urothelial transitional cell carcinoma [J].Clin Cancer Res,1998,4:559.
